Literature DB >> 7248987

Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.

J Panduro, M Hansen, H H Hansen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7248987

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  4 in total

Review 1.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

Review 2.  Chemotherapy of advanced transitional cell carcinoma of the uroepithelium.

Authors:  F M Torti; W G Harker
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer.

Authors:  B A Ponder; R T Oliver
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 4.  Chemotherapy of advanced transitional-cell carcinoma of the bladder.

Authors:  R S Miller; F M Torti
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.